The MS group showed significant elevation in the PI3K-Akt signaling pathway, MARK signaling pathway, long-term potentiation (LTP), glutamatergic synapse, and cholinergic synapse pathway. The gene discussed is MARK1; the disease is myeloid sarcoma.